NKNoël Knops

Noël Knops

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noël Knops has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Time-Varying Determinants of Graft Failure in Pediatric Kidney Transplantation in Europe

    by Ferran Coens, Noël Knops, Ineke Tieken, Serge Vogelaar, Andreas Bender, Jon Jin Kim, Kai Krupka, Lars Pape, Ann Raes, Burkhard Tönshoff, et al.

    Background: Little is known about the time-varying determinants of kidney graft failure in children. Methods: We performed a retrospective study of primary pediatric kidney transplant recipients (younger than 18 years) from the Eurotransplant registry (1990–2020). Piece-wise exponential additive mixed models were applied to analyze time-varying recipient, donor, and transplant risk factors. Primary outcome was death-censored graft failure. Results: We report on 4528 kidney transplantations, of which 68% with deceased and 32% with living donor. One thousand six hundred and thirty-eight recipients experienced graft failure, and 168 died with a functioning graft. Between 2011 and 2020, the 5-year graft failure risk was 10% for deceased donor and 4% for living donor kidney transplant recipients. Risk of graft failure decreased five-fold from 1990 to 2020. The association between living donor transplantation and the lower risk of graft failure was strongest in the first month post-transplant (adjusted hazard ratio, 0.58; 95% confidence interval, 0.46 to 0.73) and remained statistically significant until 12 years post-transplant. Risk factors for graft failure in the first 2 years were deceased donor younger than 12 years or older than 46 years, potentially recurrent kidney disease, and panel-reactive antibody >0%. Other determinants of graft failure included dialysis before transplantation (until 5 years post-transplant), human leukocyte antigen mismatch 2–4 (0–15 years post-transplant), human leukocyte antigen mismatch 5–6 (2–12 years post-transplant), and hemodialysis (8–14 years post-transplant). Recipients older than 11 years at transplantation had a higher risk of graft failure 1–8 years post-transplant compared with other age groups, whereas young recipients had a lower risk throughout follow-up. Analysis of the combined effect of post-transplant time and recipient age showed a higher rate of graft failure during the first 5 years post-transplant in adolescents compared with young transplant recipients. In contrast to deceased donor younger than 12 years, deceased donor older than 46 years was consistently associated with a higher graft failure risk. Conclusions: We report a long-term inverse association between living donor kidney transplantation and the risk of graft failure. The determinants of graft failure varied with time. There was a significant cumulative effect of adolescence and time post-transplant. The ideal donor age window was dependent on time post-transplant.


  • Open Access

    Investigating Tacrolimus Disposition in Paediatric Patients with a Physiologically Based Pharmacokinetic Model Incorporating CYP3A4 Ontogeny, Mechanistic Absorption and Red Blood Cell Binding

    by Matthias Van der Veken, Joachim Brouwers, Agustos Cetin Ozbey, Kenichi Umehara, Cordula Stillhart, Noël Knops, Patrick Augustijns, Neil John Parrott

    Tacrolimus is a crucial immunosuppressant for organ transplant patients, requiring therapeutic drug monitoring due to its variable exposure after oral intake. Physiologically based pharmacokinetic (PBPK) modelling has provided insights into tacrolimus disposition in adults but has limited application in paediatrics. This study investigated age dependency in tacrolimus exposure at the levels of absorption, metabolism, and distribution. Based on the literature data, a PBPK model was developed to predict tacrolimus exposure in adults after intravenous and oral administration. This model was then extrapolated to the paediatric population, using a unique reference dataset of kidney transplant patients. Selecting adequate ontogeny profiles for hepatic and intestinal CYP3A4 appeared critical to using the model in children. The best model performance was achieved by using the Upreti ontogeny in both the liver and intestines. To mechanistically evaluate the impact of absorption on tacrolimus exposure, biorelevant in vitro solubility and dissolution data were obtained. A relatively fast and complete release of tacrolimus from its amorphous formulation was observed when mimicking adult or paediatric dissolution conditions (dose, fluid volume). In both the adult and paediatric PBPK models, the in vitro dissolution profiles could be adequately substituted by diffusion-layer-based dissolution modelling. At the level of distribution, sensitivity analysis suggested that differences in blood plasma partitioning of tacrolimus may contribute to the variability in exposure in paediatric patients.


  • Illness-related parental stress and quality of life in children with kidney diseases

    by Elke De Bruyne, Lore Willem, Koen Van Hoeck, Sarah Reynaert, Sylvie Vankerckhove, Brigitte Adams, Stéphanie Leroi, Laure Collard, Aline Michaux, Nathalie Godefroid, et al.

    Background This cross-sectional study investigated quality of life (QoL) and illness-related parental stress in children with kidney diseases by (1) comparing mean levels of these two variables between several kidney disease categories; (2) exploring correlations between QoL and parental stress; and (3) describing which disease category reports lowest QoL and highest parental stress. Methods We included 295 patients with a kidney disease (0–18 years) and their parents, followed at 6 reference centers for pediatric nephrology. Children’s QoL was assessed by the PedsQL™ 4.0 Generic Core Scales, and illness-related stress by the Pediatric Inventory for Parents. All patients were divided into 5 kidney disease categories according to the multidisciplinary care program criteria prescribed by the Belgian authorities: (1) structural kidney diseases, (2) tubulopathies and metabolic diseases, (3) nephrotic syndrome, (4) acquired diseases with proteinuria and hypertension, and (5) kidney transplantation. Results Child self-reports showed no differences in QoL between kidney disease categories, in contrast to parent proxy reports. Parents of transplant patients reported lower QoL in their child and more parental stress compared with the 4 non-transplant categories. QoL and parental stress were negatively correlated. Lowest QoL and highest parental stress scores were mainly found in transplant patients. Conclusions This study showed lower QoL and higher parental stress in pediatric transplant patients compared with non-transplants, based on parent reports. Higher parental stress is associated with worse QoL in the child. These results highlight the importance of multidisciplinary care for children with kidney diseases, with special attention to transplant patients and their parents. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Open Access

    Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of theCYP3A5andABCB1genes

    by Noël Knops, Yasaman Ramazani, Henriëtte De Loor, Roel Goldschmeding, Tri Q Nguyen, Lambert P van Den Heuvel, Elena Levtchenko, Dirk J Kuypers

    Common genetic variants of the enzymes and efflux pump involved in tacrolimus disposition have been associated with calcineurin inhibitor nephrotoxicity, but their importance is unclear because of the multifactorial background of renal fibrosis. This study explores the pro-fibrotic response of tacrolimus exposure in relation to the differential capacity for tacrolimus metabolism in proximal tubule cells (PTCs) with a variable (pharmaco)genetic background. PTCs were obtained from protocol allograft biopsies with different combinations of CYP3A5 and ABCB1 variants and were incubated with tacrolimus within the concentration range found in vivo. Gene and protein expression, CYP3A5 and P-glycoprotein function, and tacrolimus metabolites were measured in PTC. Connective tissue growth factor (CTGF) expression was assessed in protocol biopsies of kidney allograft recipients. PTCs produce CTGF in response to escalating tacrolimus exposure, which is approximately 2-fold higher in cells with the CYP3A5*1 and ABCB1 TT combination in vitro. Increasing tacrolimus exposure results in relative higher generation of the main tacrolimus metabolite {13-O-desmethyl tacrolimus [M1]} in cells with this same genetic background. Protocol biopsies show a larger increase in in vivo CTGF tissue expression over time in TT vs. CC/CT but was not affected by the CYP3A5 genotype. Tacrolimus exposure induces a pro-fibrotic response in a PTC model in function of the donor pharmacogenetic background associated with tacrolimus metabolism. This finding provides a mechanistic insight into the nephrotoxicity associated with tacrolimus treatment and offers opportunities for a tailored immunosuppressive treatment.


  • The choice between deceased and living donor kidney transplantation in children and adolescents: a multicentric cross-sectional study

    by Dierickx Laure, Willem Lore, Raes Ann, Van Hoeck Koen, Van Cauwenberghe Katty, Vande Walle Johan, Snauwaert Evelien, Levtchenko Elena, Knops Noël, Prytula Agnieszka

    The aim of our study was to evaluate the factors influencing the choice between a deceased donor (DD) and living donor kidney transplantation (LD KT) for children and adolescents with chronic kidney disease (CKD) from the perspective of parents and physicians. Patients with CKD stages 4 and 5 at the University Hospitals of Ghent, Leuven and Antwerp were included. Between February 2019 and March 2020, the corresponding questionnaires were distributed among parents and physicians in order to evaluate the potential differences between the medical recommendation and parental choice. Twenty-eight patients (median age 11 yr, range 2–19 yr), 10 girls and 18 boys were included. Three patients had undergone kidney transplantation in the past. Parents of 13 children opted for DD and 13 LD, and in two cases, there was no preference. Physicians recommended DD in 14 cases and LD in 14 cases. Parental choice corresponded with physician’s recommendation in 22 cases. Parental reasons for choosing DD were medical (n = 7), socio-economic (n = 1), combination of both (n = 1) or no reason (n = 4). Pediatric nephrologists advised against LD for medical (n = 6) or socio-economic (n = 6) reasons or a combination of both (n = 2). In our cohort, the treating physicians regarded the family’s socio-economic factors more important for not actively promoting LD than the parents. A better understanding and communication regarding perceived socio-economic hurdles between caretakers and families might contribute to a higher incidence of living kidney donation in Belgium.

  • Bortezomib for autoimmune hemolytic anemia after intestinal transplantation

    by Noël Knops, Marie‐Paule Emonds, Jean Herman, Elena Levtchenko, Djalila Mekahli, Jacques Pirenne, Chris Van Geet, Daan Dierickx

    AIHA is rare in the general population and associated with a mortality of 8%. In contrast, AIHA occurs in up to 12.2% of cases after intestinal transplantation and is associated with mortality up to 50%. Treatment entails a “step‐up” approach including corticosteroids, IvIg, plasmapheresis, and rituximab. However, AIHA after transplantation often is refractory to this strategy, contributing to a poor outcome. We describe a child with microvillous inclusion disease who developed AIHA 1 year after multivisceral transplantation that was refractory to standard therapy and was subsequently treated with bortezomib.We observed remission of AIHA within 1 week after the start of bortezomib. Bortezomib was associated with transient diarrhea, leucopenia, and elevated liver enzymes. Three years later, he remains in remission without important complications. Published data on bortezomib for autoimmune cytopenias outside SOT are discussed. This is the first report to support bortezomib as an important therapeutic alternative for AIHA after SOT. The occurrence and treatment of AIHA after SOT, and specifically intestinal transplantation, should be the subject of future registry studies to collect additional experience and explore the optimal therapeutic approach.


  • Renal Replacement Therapy in children with severe developmental disability: guiding questions for decision-making

    by Lore Willem, Noël Knops, Djalila Mekahli, Pierre Cochat, Alberto Edefonti, Enrico Verrina, Jaap Groothoff, Lieven Lagae, Jacques Pirenne, Fabienne Dobbels, et al.

    Whether to initiate or to withhold Renal Replacement Therapy (RRT) in children with severe developmental disability (DD) remains a topic of intense debate. The present study investigated the opinion of professionals on this difficult issue and proposed a checklist with guiding questions for decision-making. Clinicians affiliated to different organizations involved in pediatric nephrology worldwide were invited to respond to a web-based survey. This survey focused on the collection of demographic data of the respondents together with their opinion concerning the decision-making regarding RRT in a particular case and for children with severe DD in general. A total of 286 professionals responded to the survey. Sixty-six percent supported initiating RRT in the child of the case report, with pre-emptive transplantation being the preferred modality. Important arguments pro RRT initiation in children with severe DD in general were parental preference, decrease of suffering, and improvement of survival and quality of life. Important contraindications included low IQ, severe comorbidities, and inability of the patient to take medication or for the family to provide sufficient care.


  • Connective tissue growth factor (CTGF) from basics to clinics

    by Yasaman Ramazani, Noël Knops, Mohamed A. Elmonem, Tri Q. Nguyen, Fanny Oliveira Arcolino, Lambert van Den Heuvel, Elena Levtchenko, Dirk Kuypers, Roel Goldschmeding


  • In vivoCYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation

    by Thomas Vanhove, Pieter Annaert, Noël Knops, Henriëtte de Loor, Jan de Hoon, Dirk R J Kuypers

    The magnitude of interaction between theCYP3A4 substrate tacrolimus and variousCYP3A4 inhibitors is highly unpredictable. We investigated whether an individual's baseline in vivoCYP3A4 activity, assessed using the oral midazolam (MDZ) probe, could be used to predict the magnitude of drug–drug interaction between tacrolimus and the potentCYP3A4 inhibitor itraconazole. In a prospective single‐arm open‐label study, 16 healthy volunteers were administered single doses ofMDZand tacrolimus before and after a 4‐day course of itraconazole. Itraconazole treatment resulted in a 9.0‐fold decrease inMDZapparent oral clearance (CL/F) and a 3.3‐fold decrease in tacrolimusCL/F (P< 0.001 for each).MDZ CL/F and tacrolimusCL/F were positively correlated both at baseline (r= 0.582,P= 0.018) and after itraconazole (r= 0.811,P< 0.001). Furthermore, baselineMDZ CL/F was positively correlated to the fold change inMDZ CL/F resulting fromCYP3A4 inhibition (r= 0.759,P= 0.001). However, no predictors of change in tacrolimusCL/F resulting fromCYP3A4 inhibition were identified, including baselineMDZ CL/F (P= 0.453), baseline tacrolimusCL/F (P= 0.759) and fold change inMDZ CL/F between both phases (P= 0.274). In conclusion, baseline oralMDZclearance does not predict the magnitude of interaction between tacrolimus and itraconazole.


  • Open Access

    Liver transplantation for very severe hepatopulmonary syndrome due to vitamin A-induced chronic liver disease in a patient with Shwachman-Diamond syndrome

    by Giorgia Bucciol, David Cassiman, Tania Roskams, Marleen Renard, Ilse Hoffman, Peter Witters, Rik Schrijvers, Heidi Schaballie, Barbara Bosch, Maria Caterina Putti, et al.

    Vitamin A intoxication is a rare cause of liver disease, but the risk increases in patients with underlying liver dysfunction. We present a patient with Shwachman-Diamond Syndrome who developed liver fibrosis, portal hypertension and very severe hepatopulmonary syndrome as a consequence of chronic vitamin A intoxication. She underwent successful liver transplantation with complete resolution of the pulmonary shunting.